Public Policy and Congressional & Executive Branch Investigations HEALTHCARE AND PHARMACEUTICALS

WilmerHale’s public policy team has extensive experience representing clients engaged in complex, high-stakes congressional and executive branch investigations, as well as those facing attorneys general and other regulators from multiple states that have banded together to investigate a particular corporation or industry. These investigations involve political and media considerations very different from those found in courtroom or regulatory litigation. We provide strategic advice that takes into account the legal and political ramifications of any given course of action, and assist clients by drafting testimony, preparing witnesses in informal sessions, conducting mock hearings, working with committee members and staff in preparation for hearings, addressing executive branch decision makers and helping to manage press coverage.

Our comparative advantage derives from three key strengths. First, we are skilled at complex policy analysis that grasps the intersections among law, policy and politics. Second, as experienced advocates, we understand how to frame arguments tailored to the audience in question—be it Congress, the Administration, the business community or the public. Finally, we have a deep bench of lawyers with significant experience at the top levels of government, so we know how to get things done in the executive branch and in Congress.


Our recent experience includes:

  • Advising a major insurance company on constitutional, substantive and strategic issues associated with efforts to achieve a global legislative solution to the national asbestos crisis
  • Assisting in the successful effort to obtain legislation protecting the confidentiality of sensitive business information provided to the government to assist in the protection of critical infrastructure
  • Advising a director of a major US healthcare corporation in connection with an investigation by the House Energy and Commerce Committee
  • Advising a medical device company in responding to congressional inquiries about its marketing practices
  • Representing a medical device company in hearings concerning dual-use technology issues